| III-01 Angela Äbelö Population concentration-QT-modelling of CHF6001 following dry powder inhalation in healthy volunteers. Thursday 09:55-11:30 |
| III-02 Nada Abla Geiser Development of PBPK drug models to support antimalarial combination strategy Thursday 09:55-11:30 |
| III-03 Amais Ahmad Evaluation of Prediction Performance of In Silico PBPK models of oral drug absorption Thursday 09:55-11:30 |
| III-04 Jae Eun Ahn Pharmacokinetic/Pharmacodynamic effects of PF-06648671, a novel gamma secretase modulator following single and multiple dose administration in healthy volunteers Thursday 09:55-11:30 |
| III-05 Yasunori Aoki Second order Taylor expansion of likelihood-based models for fast covariate and random effect model building Thursday 09:55-11:30 |
| III-06 Usman Arshad Development of visual predictive checks accounting for multimodal parameter distributions in mixture models Thursday 09:55-11:30 |
| III-07 Muhammad Waqar Ashraf A semi-PBPK model to describe the mechanism based drug-drug interaction between S-ketamine and ticlopidine in healthy human volunteers. Thursday 09:55-11:30 |
| III-08 Magnus Ĺstrand Longitudinal pharmacometric modelling of serum potassium lowering effect of sodium zirconium cyclosilicate in patients with hyperkalemia Thursday 09:55-11:30 |
| III-09 Linda Aulin Quantitative modelling of procalcitonin as a treatment response biomarker in sepsis Thursday 09:55-11:30 |
| III-10 Geraldine Celliere Development of guidelines to efficiently choose and diagnose target-mediated drug disposition models Thursday 09:55-11:30 |
| III-11 Vanessa Baier Developing a physiology-based model of bile acid metabolism in men Thursday 09:55-11:30 |
| III-12 Pavel Balazki A Physiologically-based Quantitative Systems Pharmacology model of the incretin hormones GLP-1 and GIP Thursday 09:55-11:30 |
| III-13 Belén Pérez Solans Mechanistic model of the myeloablative effects of treosulfan and busulfan in pediatric patients undergoing bone marrow transplant Thursday 09:55-11:30 |
| III-14 Irina Baltcheva Model-based dose selection for the Phase 2b study of ianalumab in primary Sjögren's Syndrome Thursday 09:55-11:30 |
| III-15 Guillaume Baneyx Target-mediated drug disposition modeling of lacnotuzumab in healthy volunteers and patients with advanced malignancies and triple negative breast cancer. Thursday 09:55-11:30 |
| III-16 Catalina Barceló Modelling waist-hip ratio increase in HIV-infected individuals starting antiretroviral therapy Thursday 09:55-11:30 |
| III-17 Christian Bartels ggPMX: a toolbox to easily generate a comprehensive set of model diagnostic plots for population models Thursday 09:55-11:30 |
| III-18 Roberta Bartolucci A PBPK model for the study of Azathioprine pharmacokinetics in rats and prediction in humans Thursday 09:55-11:30 |
| III-19 Carla Bastida Fernández PK/PD of the individual components of composite indexes variables used for disease activity assessment in rheumatoid arthritis patients on tocilizumab treatment. Thursday 09:55-11:30 |
| III-20 Ryan Beechinor A population pharmacokinetic study of high dose methotrexate treatment in infants with acute lymphoblastic leukemia: The importance of modeling inter-occasion variability across treatment cycles Thursday 09:55-11:30 |
| III-21 Amina Bensalem Concentration-effect relationships of therapeutic monoclonal antibody rituximab in rheumatoid arthritis. Thursday 09:55-11:30 |
| III-22 Agathe Béranger Piperacillin dosing regimen optimization in critically ill children according to different creatinine clearances Thursday 09:55-11:30 |
| III-23 Agnieszka Bienert Pharmacokinetics of dexmedetomidine in elderly patients undergoing sedation after abdominal aortic surgery. Thursday 09:55-11:30 |
| III-24 Robert Bies Pharmacokinetic-pharmacodynamic modelling of MK-2048 in ex vivo cervical tissue Thursday 09:55-11:30 |
| III-25 Henrik Bjugĺrd Nyberg A pediatric population pharmacokinetic model for ethionamide in South African children treated for drug-susceptible or drug-resistant tuberculosis. Thursday 09:55-11:30 |
| III-26 Alessandro Boianelli A quantitative systems pharmacology model for understanding the role of dietary fructose metabolism in NAFLD Thursday 09:55-11:30 |
| III-27 Charlotte Bon Capacity limits of ASGPR mediated liver targeting Thursday 09:55-11:30 |
| III-28 Rolien Bosch A novel integrated QSP model of in vivo human glucose regulation to support development of a glucagon/GLP-1 dual agonist. Thursday 09:55-11:30 |
| III-29 Ari Brekkan Viggosson Characterization of anti-drug antibodies using a bivariate mixed hidden Markov model Thursday 09:55-11:30 |
| III-30 Philippine Eloy Genetics of nevirapine and anti-tuberculosis drugs pharmacokinetics interaction in HIV-tuberculosis co-infected patients in Mozambique Thursday 09:55-11:30 |
| III-31 Hannah Britz Physiologically-based pharmacokinetic (PBPK) modeling of the strong CYP1A2 inhibitor fluvoxamine Thursday 09:55-11:30 |
| III-32 Astrid Broeker An integrated pharmacometric dialysis model to evaluate the pharmacokinetic impact of renal replacement therapy Thursday 09:55-11:30 |
| III-33 Jantine Brussee Dose Individualization of CYP3A Substrates in Children: Characterization of Maturation of Intestinal and Hepatic CYP3A Activity in Children to Predict First-pass and Systemic CYP3A-mediated Metabolism Thursday 09:55-11:30 |
| III-34 Thierry Buclin Closed-loop control for propofol administration during anesthesia based on real-time concentration measurement: a simulation study Thursday 09:55-11:30 |
| III-35 Wonkyung Byon Apixaban for treatment of venous thromboembolism (VTEtx): Use of Model-Based Meta-Analysis (MBMA) to support Phase 3 dose selection and beyond Thursday 09:55-11:30 |
| III-36 Tim Cardilin Modeling of radiation therapy and radiosensitizing agents in tumor xenografts Thursday 09:55-11:30 |
| III-37 Evelina Cardoso Population pharmacokinetic analysis of erlotinib in cancer patients affected by NSCLC Thursday 09:55-11:30 |
| III-38 Marc Cerou HAM-D score analysis of patients under placebo with major depressive disorder using item response theory Thursday 09:55-11:30 |
| III-39 Blesson Chacko Covariate effects on competing events: a simulation study comparing approaches Thursday 09:55-11:30 |
| III-40 Dong Woo Chae Predictive Modeling of PCA Effect on Postoperative Pain Management Thursday 09:55-11:30 |
| III-41 Anne Chain Extension of population pharmacokinetic analysis of pembrolizumab to paediatric patients patients with classical Hodgkin lymphoma Thursday 09:55-11:30 |
| III-42 Pascal Chanu Pediatric plans optimization of C.E.R.A. (Continuous Erythropoietin Receptor Activator): clinical evidence obtained through a model-based integration of multisource data Thursday 09:55-11:30 |
| III-43 Estelle Chasseloup Generation and Application of Avatars (Digital Twins) in Pharmacometric Modelling Thursday 09:55-11:30 |
| III-44 Jonathan Chauvin COSSAC (COnditional Sampling use for Stepwise Approach based on Correlation tests) method for covariate search Thursday 09:55-11:30 |
| III-45 Chee Ng Novel Multilevel Parallel Expectation Maximization (MPEM) Estimation Methods for Population Quantitative Pharmacology Analysis Thursday 09:55-11:30 |
| III-46 Wenjun Chen Modeling the antitumor efficacy and pharmacokinetic/pharmacodynamic interaction between docetaxel and cabozantinib in human prostate cancer xenograft mouse models Thursday 09:55-11:30 |
| III-47 Mohammed Cherkaoui Rbati A Liver Model for Chemoprotection Against Malaria Thursday 09:55-11:30 |
| III-48 Manoranjenni Chetty Antidepressants, anxiolytics and statins: prediction of exposure changes due to aging Thursday 09:55-11:30 |
| III-49 S. Y. Amy Cheung Challenges and opportunities in the development of medical therapies for paediatric populations and the role of extrapolation Thursday 09:55-11:30 |
| III-50 Maxwell Chirehwa Correlates of tuberculosis treatment outcomes: application of regression trees and pharmacodynamic modelling techniques Thursday 09:55-11:30 |
| III-51 Jason Chittenden PMDatR: A Pharmacometric Data Manipulation Package for R Thursday 09:55-11:30 |
| III-52 Young-Kyung Choi Population pharmacokinetics of cycloserine in patients with multidrug-resistant tuberculosis Thursday 09:55-11:30 |
| III-53 Francois Combes Modeling and Simulation Approach of Everolimus PK/PD Toward Completing a Pediatric Development Thursday 09:55-11:30 |
| III-54 Valerie Cosson Population PKPD modeling of RO7046015 (PRX002/RG7935), an Anti--Synuclein Monoclonal Antibody for the treatment of Parkinson’s Disease Thursday 09:55-11:30 |
| III-55 Perrine Courlet Comparison of escitalopram pharmacokinetics in HIV infected individuals with an uninfected psychiatric cohort Thursday 09:55-11:30 |
| III-56 Vincent Croixmarie Use of a multivariate distribution to simulate severe renal impaired patients Thursday 09:55-11:30 |
| III-57 Ailing Cui Quantitative Predictive Models for the Degree of Disability After Acute Ischemic Stroke Thursday 09:55-11:30 |
| III-59 André Dallmann Characterization of paracetamol hepatotoxicity during pregnancy through physiologically-based pharmacokinetic modeling Thursday 09:55-11:30 |
| III-60 Daniel Kaschek An Integrated R-Based Framework for Model Development in Health Economics Thursday 09:55-11:30 |
| III-61 Kim Dao Evaluation of exposure to vancomycin in neonates under existing dosing regimens using a population pharmacokinetic approach Thursday 09:55-11:30 |
| III-62 Olivier David A PKPD model describing the amyloid precursor protein (APP) derived peptides in subjects receiving CNP520, a BACE-1 inhibitor. Thursday 09:55-11:30 |
| III-63 Nico de Jager Population pharmacokinetic modelling of factor VIII levels during perioperative dosing of Haemate® P (Humate P) in patients diagnosed with von Willebrands Disease. Thursday 09:55-11:30 |
| III-64 Giuseppe De Nicolao Analysis of muscular biopsy distributional data in Duchenne Muscular Dystrophy treatment: a population approach Thursday 09:55-11:30 |
| III-65 Mailys De Sousa Mendes Mechanistic modelling of in-vitro bidirectional permeability studies and in vivo absorption of metoprolol Thursday 09:55-11:30 |
| III-66 Elien De Thaye In vitro data supporting circulating CCCK18 as potential pharmacodynamic biomarker in ovarian cancer Thursday 09:55-11:30 |
| III-67 Aurelia de Vries Schultink Therapeutic drug monitoring of endoxifen in ER-positive breast cancer patients: comparing data from clinical practice to model-based predictions. Thursday 09:55-11:30 |
| III-68 Neel Deferm A Mechanistic Cellular Disposition Model of Bile Acid Handling in Sandwich-Cultured Human Hepatocytes Thursday 09:55-11:30 |
| III-69 Oleg Demin Simulations of tau-targeted therapies using quantitative systems pharmacology model of tau pathology Thursday 09:55-11:30 |
| III-70 Oleg Demin Jr Quantitative Systems Pharmacology Modeling of CAR-T Therapy and T Cell Engaging Bispecific Antibodies: B-cell Acute Lymphoblastic Leukemia Case Study Thursday 09:55-11:30 |
| III-71 Aris Dokoumetzidis Population pharmacokinetics of teicoplanin in preterm and term neonates with late-onset sepsis Thursday 09:55-11:30 |
| III-72 Artem Dolgun A functional, integrative R environment workflow for the development and use of quantitative systems pharmacology models Thursday 09:55-11:30 |
| III-73 Anne-Gaelle Dosne Optimizing Biomarker-Based Dosing Algorithm for Erdafitinib through PK-PD Modeling and Simulations Thursday 09:55-11:30 |
| III-74 Erwin Dreesen Development of a population pharmacokinetic and pharmacodynamic model to describe the effect of infliximab induction therapy on mucosal healing in patients with ulcerative colitis Thursday 09:55-11:30 |
| III-75 Vincent Dubois Comparative attributes of a semimechanistic and an empirical population PK model for durvalumab, a fully human anti-PD-L1 monoclonal antibody Thursday 09:55-11:30 |
| III-76 Miro Eigenmann Dynamic in vitro PKPD assessment to improve pharmacological response profiling of T-cell bispecifics Thursday 09:55-11:30 |
| III-77 Salvatore D'Agate Development of a drug-disease model describing individual IPSS trajectories in BPH patients: Implication of disease progression and covariate factors on long term treatment response Thursday 09:55-11:30 |
